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sion, impair bone health or does stress-induced disruption of bone 
homeostasis come first? Both perspectives are highly relevant for 
the medical care of patients [4], and their study requires the defini-
tion of relevant outcomes.
Present stress concepts state that neuroendocrine signaling 
pathways are activated by stress in an attempt to enable mental as 
well as physical adaptation and maintain a low allostatic load. 
However, persistent excessive or prolonged stresses (e.g., traumat-
ic life events, chronic work strain triggering a depressive episode) 
can provoke a maladaptive increase of neuroendocrine responses, 
toxic systemic stress, and an accumulation of allostatic load [5]. It 
is evident that specific allostatic load mediators, such as cortisol, 
growth hormone, or insulin-like growth factor-I, may play a role 
in the lifelong remodeling process of bones [6, 7]. Elevated cortisol 
levels can inhibit osteoblast proliferation, differentiation, and 
apoptosis, leading to decreased bone density. However, whether 
such allostatic overload occurs depends largely on exposure inten-
sity and duration, personal and social resources (coping, expo-
some), and epigenetic adaptability [8]. In other words, stressful life 
events do not necessarily lead to depressive disorders or allostatic 
overload, especially if the neuroendocrine response enables adap-
tion and can be turned off after an appropriate interval [9].
Here, we therefore aimed to study whether bone metabolism is 
changed during an acute depressive episode and whether people 
with a high life burden and allostatic load show alterations in bone 
metabolism and mineral density. Further, we wanted to know 
whether a mathematical algorithm can determine individual allo-
static load mediators that identify patients at higher risk for dis-
rupted bone metabolism and thereby optimize medical care.
In an 18-month, multicenter, observational study, we assem-
bled a cohort of two hundred and eight 18- to 65-year-old depres-
sive patients in the primary care setting suffering from severe to 
moderate depression (mainly ICD-10 F32.x or F33.x). We deter-
mined psychosomatic symptoms (Beck Depression Inventory-II 
[BDI-II]; Symptom Check List – revised [SCL-90-R]: Positive 
Symptom Distress Index [PSDI], Global Severity Index [GSI], and 
Positive Symptom Total [PST]), life burden (Inventory of Life 
Changing Events ), and allostatic load index (ALI; derived from 15 
neuroendocrinological, immunological, and metabolic allostatic 
mediators). Bone metabolism was measured by 3 bone formation 
and resorption serum markers (osteocalcin [OC], procollagen type 
1 N-terminal propeptide [P1NP], and β-CrossLaps [CTx]). BMD 
was assessed in both hips and the lumbar spine (subsample, n = 18; 
DXA BMD-L1L4, -TMW, -SMW, -GMW, and -HMW). Descrip-
tive statistics, paired sample t tests, multivariable regression mod-
els, and Least Absolute Shrinkage and Selection Operator (LASSO) 
were applied for analyzing the study questions.
65% of our patients (mean age = 46.63, SD = 11.13, f = 75%) 
suffered from severe to moderate depression (mean BDI-II = 
23.61, SD = 10.14), severe psychosomatic symptoms (GSI: 41.8%; 
PSDI: 42.3%), and allostatic load burden (ALI: 29.3%). Higher life 
Depression is a severe and highly comorbid condition that af-
fects mental and physical health and is a prime cause of disability. 
Regarding the pathogenesis of comorbid depressive disorders, pre-
vious research has shown that neuroendocrine and neuroanatom-
ical responses to stress lead to cellular and molecular changes that 
promote the development of comorbid diseases [1]. Hence, de-
pressive disorders may influence the homeostasis of tissues, in-
cluding bone, and contribute, for example, to osteoporosis devel-
opment [2, 3] and decreased bone mineral density (BMD) [4]. 
However, the present knowledge of involved pathogenetic mecha-
nisms is still scarce, and studies are required that provide a better 
understanding of possible interactions between depression, neu-
roendocrine stress responses, and bone metabolism. Moreover, it 
is unclear what comes first: does mental distress, such as depres-
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burden was associated with depressive disorder (BDI-II: b = 0.24 
[95% CI 0.064, 0.411], p = 0.008) but not with allostatic load.
In this cohort, we observed that higher depression (OC: b = 0.08 
[95% CI –0.008, 0.173], p = 0.075) and symptom severity (PSDI: 
P1NP: b = 5.30 [95% CI –0.59, 11.19], p = 0.081; OC: b = 0.91 [95% 
CI 0.86, 4.41], p = 0.005; CTX: b = 0.052 [95% CI 0.011, 0.093], 
p = 0.016; GSI: OC: b = 2.10 [95% CI 0.45, 3.75], p = 0.015) were 
associated with a higher expression of anabolic bone metabolism 
(OC; P1NP; CTx). People with a high life burden showed signifi-
cantly less anabolic expression (OC: b = 0.11 [95% CI 0.017, 0.206], 
p = 0.021; CTx: b = 0.002 [95% CI 0.000, 0.004], p = 0.049).
At the same time, patients with high allostatic load showed a 
significantly decreased bone metabolism (ALI: OC: b = –0.46 [95% 
CI –0.864, –0.059], p = 0.027; CTx: b = –0.01 [95% CI –0.018, 
0.001], p = 0.065) and reduced BMD in the lumbar spine and both 
hips (DXA). LASSO could not identify any singular allostatic load 
mediator sufficient enough for the prediction of bone metabolism 
quality (OC; P1NP; CTx) 1.5 years after baseline (Table 1).
The findings suggest that anabolic activation of bone metabo-
lism occurs during a depressive episode, which increases with the 
severity of the depression and psychosomatic symptoms. This so 
far undiscovered metabolic adaptation to an exceptionally high 
stress episode is limited to patients with a higher life burden and 
completely absent in patients with allostatic overload. The latter 
are – presumably due to the accumulation of toxic stress in tissues 
and cells – no longer capable of an adequate metabolic adaptation. 
Thus, a catabolic and bone damaging process occurs, which is re-
flected by a reduction of BMD in the long term.
The fact that predominantly patients with acute and nonchron-
ic depressive disorder were involved in the study enabled the dis-
covery of this highly important mechanism that is believed to affect 
corresponding medical therapies (drug administration, exercise, 
etc.). The data provide further evidence that a gradation between 
different levels of physical and mental load accumulation must be 
respected. However, many questions remain unanswered and 
should be investigated in further studies. For example, no diagnos-
tic instrument could be derived from the allostatic mediators. In 
addition, further studies should examine to what extent psycho-
metric data would allow diagnostic assessments [9].
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Table 1. Main effects (regression coefficient b) of depressiveness, life events, psychosomatic symptoms severity, and ALIs on bone mark-
ers at baseline (t0)
P1NP OC CTx
coefficient 95% CI p coefficient 95% CI p coefficient 95% CI p
BDI-II sum score 0.121 –0.170, 0.413 0.417 0.083 –0.008, 0.173 0.075 0.0004 –0.002, 0.002 0.727
SCL-90-R PSDI 5.304 –0.585, 11.194 0.081 2.631 0.855, 4.407 0.005 0.052 0.011, 0.093 0.016
SCL-90-R PST 0.061 –0.134, 0.256 0.543 0.045 –0.015, 0.105 0.145 –0.0002 –0.002, 0.001 0.729
SCL-90-R GSI 3.222 –2.103, 8.548 0.239 2.096 0.447, 3.745 0.015 0.020 –0.020, 0.059 0.333
ILE alla 0.158 –0.153, 0.470 0.317 0.111 0.017, 0.206 0.021 0.002 0.000, 0.004 0.049
ALI 21 –0.523 –1.650, 0.604 0.365 –0.438 –0.779, –0.096 0.014 –0.009 –0.017, –0.001 0.025
ALI 15 –0.435 –1.759, 0.888 0.521 –0.462 –0.864, –0.059 0.027 –0.009 –0.018, 0.0005 0.065
ALI-II –0.351 –1.585, 0.884 0.579 –0.492 –0.875, –0.108 0.014 –0.008 –0.017, 0.001 0.088
ALI-I 0.734 –1.824, 3.291 0.576 0.467 –0.318, 1.253 0.246 –0.005 –0.023, 0.014 0.614
Multiple interaction regression models, adjusted for age, gender, and study sites. Significant regression coefficients are bold (p < 
0.01, p < 0.05, p < 0.10; 2-sided testing). ALI, allostatic load index; BDI-II, Beck Depression Inventory II; SCL-90-R, Symptom Check 
List – revised; PSDI, Positive Symptom Distress Index; PST, Positive Symptom Total; GSI, Global Severity Index; ILE, Inventory of Life 
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